NCT00724425View on ClinicalTrials.gov

A Phase 1 Dose Escalation Study of IPI-493

PHASE1TerminatedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Advanced Malignancies
Interventions
DRUG

IPI-493

Capsules, Multiple Schedules

Trial Locations (5)

75201

Mary Crowley Cancer Research Center, Dallas

80045

Univeristy of Colorado Health Science Center, Aurora

85260

Premiere Oncology, Arizona, Scottsdale

90404

Premiere Oncology, California, Santa Monica

92024

San Diego Pacific Oncology and Hematology Associates, Encinitas

Sponsors
All Listed Sponsors
lead

Infinity Pharmaceuticals, Inc.

INDUSTRY

NCT00724425 - A Phase 1 Dose Escalation Study of IPI-493 | Biotech Hunter | Biotech Hunter